Nkarta (NKTX)
(Delayed Data from NSDQ)
$5.97 USD
-0.16 (-2.61%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $5.98 +0.01 (0.17%) 7:38 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Brokerage Reports
Nkarta, Inc. [NKTX]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Focus is on NKX019 Phase 1 Data in LN on First Patient Dosed in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
New Translational Data Validate That CAR-NK Therapy Could be Ideally Suited For Autoimmune Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Prioritizing Autoimmune Diseases For Development Moving Forward; 4Q23 Financials Reported
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
NKX019 Demonstrates Deep B Cell Aplasia in NHL Patients; Increasing PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Durability for NKX101 Flu/Ara-C Cohort Presented at ASH Looks Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: AML Flu/Ara-C Update to Be Presented at ASH; Updates Across the Pipeline Expected in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Nkarta Joins the Race for Cell Therapies in Autoimmune Diseases; Setback in NHL Leads Us to Lower Our PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: NKX019 Data Update Expected in 2H23 and NKX101 Update Expected in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
NKX101 Flu/Cy Data Disappoint Though Initial Flu/ Ara-C Cohort Data Look Positive; Lowering PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Recap: NKX101 AML Data in 2Q23 Could be a Significant Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: We Believe Expectations For AML Data in 1H23 are Low, Creating an Attractive Buying Opportunity
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Winning Data Streak Continues With Positive NKX019 Phase 1 Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Take: Additional NKX019 Data Expected in 4Q22 and NKX101 Data Expected 1H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Take: Additional Data From NKX101 and NKX019 Expected 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Take: Additional NKX101 and NKX019 Data Expected in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
Two Solid Data Sets Are Better Than One, Increasing PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Take: NKX101 Data in 1H22 Could Be a Major De-Risking Event for the Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
CAR-NK Therapy Could Potentially Take CART Therapy Off-the-Shelf; Initiate at Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Nkarta, Inc.
Industry: Medical - Biomedical and Genetics
|